AUM Biosciences is already in collaboration with several high profile pharmaceutical companies for various research and drug trial applications.
Collaboration with A*STAR’s Experimental Therapeutics Centre (ETC) - AUM has global rights to develop, commercialise and manufacture ETC-206 in all indications. ETC-206 was discovered and developed through a collaboration between A*STAR’s Experimental Therapeutics Centre (ETC) and Duke-NUS Medical School (a partnership between Duke University School of Medicine and the National University of Singapore). ETC-206 is the first in AUM’s pipeline of novel targeted therapies with the potential to be developed both independently and in combination with other therapies.
Partnership with National Cancer Center Singapore (NCCS) - AUM Biosciences' partnership with NCC Singapore is expected to employ precision and digital medicine techniques that can develop cancer drugs in a shorter time frame. It will combine NCCS’ Patient Derived Xenograft (PDX) laboratory model capabilities and knowledge on drug discovery with AUM's expertise in clinical drug development. PDX entails grafting of patients’ tumors onto mice, thereby creating valuable human cancer or PDX models. Different drugs can then be tested in these PDX models to evaluate their ability to inhibit tumor growth.
Partnership with The Centre for Cellular and Molecular Platforms (C-CAMP) - AUM has partnered with C-CAMP, India’s premier bio-innovation hub to further strengthen our focus on the pre-clinical development of small molecules as anti-cancer drugs.
With this collaboration, AUM will have access to ongoing oncology research and drug development in the Indian biotechnology arena and jointly develop small molecules as drugs for cancer therapy for patients in need across the world. This is a unique partnership which will benefit both the organisations in the R&D front and commercial front.
Inflection Biosciences Ltd, based in Dublin, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the first-in-class dual mechanism kinase inhibitors AUM-300 series (PIM/PI3K/mTOR inhibitors) partnered with AUM Biosciences, and internal programs IBL-202 (PIM/PI3K inhibitor) and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com.